Organon & Co.
OGN
NYSE·Healthcare·Drug Manufacturers - General·Mkt cap $3.6B
$13.78
▲ +0.07%
P/E
14.21
Mkt Cap
$3.6B
52-Wk Range
$5.69–$13.79
52-Week Range
$5.69 - $13.79
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 31.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Above-average volatility (beta 1.5).
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Stable
+3.1% over 3m
Quality
Strong
Strong fundamentals
Dividend
Modest
0.58% yield
Smart-money signal
Who's buying OGN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
JUL 31, 2026
Reported EPS of $0.41 vs $0.91 consensus (-55.0% surprise). Revenue of $1.6B vs $1.6B expected (-0.8%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-55.0%
Revenue trend · last 2Q
—
-100%
Q1 26
Q2 26
$1.5B
$1.6M
Margins · last 2Q
Gross
54.4%
Operating
20.7%
Profit
6.9%
Wall Street consensus
2 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: BNP Paribas · Apr 29, 2026
vs Industry
How OGN stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.